- Oops!Something went wrong.Please try again later.
The drug candidate, HCW9218, is an injectable, fusion protein complex designed to drive bifunctional, anti-tumor activity while simultaneously blocking unwanted immunosuppressive activities.
In preclinical studies, HCW9218 enhanced the anti-tumor efficacy of chemotherapy docetaxel and gemcitabine plus nab-paclitaxel against melanoma and pancreatic cancer, respectively, and simultaneously alleviated the off-target, unwanted effects of chemotherapies on normal tissues.
In animal models, HCW9218 also augmented anti-tumor activities of therapeutic and checkpoint antibodies.
Related content: Benzinga's Full FDA Calendar.
Price Action: HCWB shares are up 101.4% at $5.88 during the market session on the last check Thursday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.